However, patients with brain metastases could benefit from immunotherapy only in a subset of subgroups (ie, immune monotherapy, NSCLC, median follow-up > 20 months, and targeting PD-L1) (Figure 3A). Here, CD274 is linked to non-small cell lung carcinoma.